Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Equity (2016 - 2025)

Historic Return on Equity for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to 0.25%.

  • CytomX Therapeutics' Return on Equity rose 7500.0% to 0.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25%, marking a year-over-year increase of 7500.0%. This contributed to the annual value of 1.33% for FY2024, which is 13400.0% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Return on Equity stood at 0.25%, which was up 7500.0% from 0.66% recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Return on Equity registered a high of 8.25% during Q1 2022, and its lowest value of 7.73% during Q4 2021.
  • Its 5-year average for Return on Equity is 0.1%, with a median of 0.15% in 2023.
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 109300bps in 2022, then crashed by -74300bps in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Return on Equity stood at 7.73% in 2021, then soared by 115bps to 1.19% in 2022, then tumbled by -99bps to 0.01% in 2023, then plummeted by -23219bps to 2.67% in 2024, then soared by 109bps to 0.25% in 2025.
  • Its Return on Equity was 0.25% in Q3 2025, compared to 0.66% in Q2 2025 and 3.38% in Q1 2025.